Compare · ABT vs EVMN
ABT vs EVMN
Side-by-side comparison of Abbott Laboratories (ABT) and Evommune Inc. (EVMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and EVMN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $180.95B, about 636.1x EVMN ($284.5M).
- EVMN has been more active in the news (24 items in the past 4 weeks vs 11 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 15 for EVMN).
- Company
- Abbott Laboratories
- Evommune Inc.
- Price
- $103.91-0.56%
- -
- Market cap
- $180.95B
- $284.5M
- 1M return
- +3.11%
- -
- 1Y return
- -17.80%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 11
- 24
- Recent ratings
- 25
- 15
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis
- Abbott Labs upgraded by Leerink Partners with a new price target
- Abbott Laboratories filed SEC Form 8-K: Leadership Update
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
Latest EVMN
- Director Arthur S Kirsch returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)
- Director David E Cohen returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)
- Director Benjamin F Mcgraw III returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)
- Chief of Dev. Operations Janice Suzann Drew returned 305,166 stock options to the company and was granted 305,166 stock options (SEC Form 4)
- Chief Scientific Officer Jeegar Pravinkumar Patel returned 248,934 stock options to the company and was granted 248,934 stock options (SEC Form 4)
- Chief Financial Officer Kyle Carver returned 378,354 stock options to the company and was granted 378,354 stock options (SEC Form 4)
- Chief Business & Legal Officer Gregory S. Moss returned 408,775 stock options to the company and was granted 408,775 stock options (SEC Form 4)
- Chief Medical Officer Eugene Bauer returned 151,117 stock options to the company and was granted 151,117 stock options (SEC Form 4)
- President & CEO Luis C. Pena returned 1,088,261 stock options to the company and was granted 1,088,261 stock options (SEC Form 4)
- SEC Form 424B3 filed by Evommune Inc.